Estimated risk of a first stroke and conditioning factors in Spanish hypertensive women. The RIMHA study

Blood Pressure

Volumn 15, Issue 4, 2006, Pages 237-244

  Coca, Antonio ^a,g   REDó N, Josep ^b   Cea Calvo, Luis ^c   Lozano, Jose V ^d   Navarro, Jorge ^e   Fernandez Perez, Cristina ^f   Bonet, Alvaro ^e   Gonzalez Esteban, Jorge ^c  

^a UNIVERSITY OF BARCELONA   (Spain)

^b UNIVERSITY OF VALENCIA   (Spain)

^c Medical affairs Merck sharp and Dohme ltd   (Spain)

^d SerrerÍa 2 Health Care Center   (Spain)

^e Salvador Pau Health Care Center   (Spain)

^f UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^g HOSPITAL CLÍNIC   (Spain)

Author keywords

Cardiovascular risk; Hypertension; Stroke; Women

Indexed keywords

AGE; AGED; ARTICLE; BLOOD PRESSURE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CORONARY ARTERY DISEASE; CROSS-SECTIONAL STUDY; DRUG EFFECT; FEMALE; HEART ATRIUM FIBRILLATION; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; MIDDLE AGED; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; RISK; RISK FACTOR; SPAIN; STATISTICAL MODEL;

AGE FACTORS; AGED; ATRIAL FIBRILLATION; BLOOD PRESSURE; CEREBROVASCULAR ACCIDENT; CORONARY DISEASE; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; LINEAR MODELS; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; RISK FACTORS; SPAIN;

EID: 39049194009     PISSN: 08037051     EISSN: 16511999     Source Type: Journal    
DOI: 10.1080/08037050600913474     Document Type: Article

References (39)

1. Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: A meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360:1903-1913
2. Kannel WB. Blood pressure as a cardiovascular risk factor: Prevention and treatment. JAMA. 1996;275:1571-1576 (Pubitemid 26154243)
3. Collins R, Peto R, MacMahon S, Hebert P, Fiebach NH, Eberlein KA, et al. Blood pressure, stroke, and coronary heart disease. Part 2, Short-term reductions in blood pressure: Overview of randomised drug trials in their epidemiological context. Lancet. 1990;335:827-838 (Pubitemid 20113741)
4. Staessen JA, Wang JG, Thijs L, Fagard R. Overview of the outcome trials in older patients with isolated systolic hypertension. J Hum Hypertens. 1999;13:859-863 (Pubitemid 30028954)
5. Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, et al. Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol. Lancet. 2002;359:995-1003 (Pubitemid 34286536)
6. Schrader J, Luders S, Kulschewski A, Hammersen F, Plate K, Berger J, et al. Morbidity and mortality after stroke, eprosartan compared with nitrendipine for secondary prevention: Principal results of a prospective randomized controlled study (MOSES). Stroke. 2005;36:1218-1226
7. Warlow C, Sudlow C, Dennis M, Wardlaw J, Sandercock P. Stroke. Lancet. 2003;362:1211-1224 (Pubitemid 37255350)
8. World Health Organization. The atlas of heart disease and stroke. Available at http://www.who.int/cardiovascular-diseases/resources/atlas/en/ index.html. Accessed on 15 April 2005
9. Wolf-Maier K, Cooper RS, Kramer H, Banegas JR, Giampaoli S, Joffres MR, et al. Hypertension treatment and control in five European countries, Canada, and the United States. Hypertension. 2004;43:10-17 (Pubitemid 38031904)
10. Wolf-Maier K, Cooper RS, Banegas JR, Giampaoli S, Hense HW, Joffres M, et al. Hypertension prevalence and blood pressure levels in 6 European countries, Canada, and the United States. JAMA. 2003;289:2363-2369 (Pubitemid 37430168)
11. Regidor E, Gutiérrez-Fisac JL, Calle ME, Otero A. Mortality patterns in Spain, 1998. Med Clin (Barc). 2002;118:13-15
12. National Statistics Center 2005. Available at: http://193.146.50.130/ htdocs/cardiov/cardiov1.htm. Accesed on 15 April 2005
13. D'Agostino R, Wolf PA, Belanger A, Kannel W. Stroke risk profile: Adjustment for antihipertensive medication. The Framinghan Study. Stroke. 1994;25:40-43
14. Lozano JV, Redon J, Cea-Calvo L, Fernandez-Perez C, Navarro J, Bonet A, et al. Estimation of risk for the first stroke in the Spanish hypertensive population visited by primary care physicians. The ERIC-HTA study. Med Clin (Barc). 2005;125:247-251 (Pubitemid 41353717)
15. Levey AS, Coresh J, Balk E, Kausz AT, Levin A, Steffes MW, et al. National Kidney Foundation practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. Ann Intern Med. 2003;139:137-147
16. National Kidney Foundation. GRF carculator. Available at http://www.kidney.org/professionals/kdoqi/gfr-calculator.cfm. Accesed on 15 April 2006
17. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation. 1998;97: 1837-1847 (Pubitemid 28213628)
18. Conroy RM, Pyorala K, Fitzgerald AP, Sans S, Menotti A, De Backer G, et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: The SCORE project. Eur Heart J. 2003;24:987-1003 (Pubitemid 36712275)
19. Mancia G, Ambrosioni E, Rosei EA, Leonetti G, Trimarco B, Volpe M. Blood pressure control and risk for stroke in untreated and treated hypertensive patients screened from clinical practice: Results of the ForLife study. J Hypertens. 2005;23:1575-1581 (Pubitemid 41104830)
20. Kjeldsen S, Julius S, Hedner T, Hansson L. Stroke is more common than myocardial infarction in hypertension: Analysis based on 11 major randomized intervention trials. Blood Press. 2001;10:190-192 (Pubitemid 33149897)
21. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288:2981-2997
22. Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: The VALUE randomised trial. Lancet. 2004;363:2022-2031 (Pubitemid 38781102)
23. Dahlof B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): A multicentre randomised controlled trial. Lancet. 2005;366: 895-906 (Pubitemid 41265663)
24. Hansson L, Lindholm LH, Ekbom T, Dahlof B, Lanke J, Schersten B, et al. Randomised trial of old and new antihypertensive drugs in elderly patients: Cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. Lancet. 1999;354: 1751-1756
25. Hansson L, Lindholm LH, Niskanen L, Lanke J, Hedner T, Niklason A, et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: The Captopril Prevention Project (CAPPP) randomised trial. Lancet. 1999;353:611-616 (Pubitemid 29087980)
26. Coca A. Blood pressure control at primary care in Spain. The 2003 Controlpress study. Hipertensión. 2005;22:5-14
27. Roux O, Chapellier M, Czernichow S, Nisse-Durgeat S, Safar ME, Blacher J. Determinants of hypertension control in a large French population of treated hypertensive subjects. Blood Press. 2006;15:6-13
28. Macedo ME, Lima MJ, Silva AO, Alcantara P, Ramalhinho V, Carmona J. Prevalence, awareness, treatment and control of hypertension in Portugal: The PAP study. J Hypertens. 2005;23:1661-1666 (Pubitemid 41233425)
29. Steckelings UM, Stoppelhaar M, Sharma AM, Wittchen HU, Krause P, Kupper B, et al. HYDRA: Possible determinants of unsatisfactory hypertension control in German primary care patients. Blood Press. 2004;13:80-88 (Pubitemid 38607703)
30. Primatesta P, Poulter NR. Improvement in hypertension management in England: Results from the Health Survey for England 2003. J Hypertens. 2006;24:1187-1192 (Pubitemid 43772327)
31. Okin PM, Devereux RB, Jern S, Kjeldsen SE, Julius S, Dahlof B. Baseline characteristics in relation to electrocardiographic left ventricular hypertrophy in hypertensive patients: The Losartan intervention for endpoint reduction (LIFE) in hypertension study. The Life Study Investigators. Hypertension. 2000;36:766-773
32. Verdecchia P, Porcellati C, Reboldi G, Gattobigio R, Borgioni C, Pearson TA, et al. Left ventricular hypertrophy as an independent predictor of acute cerebrovascular events in essential hypertension. Circulation. 2001;104: 2039-2044 (Pubitemid 33027044)
33. Levy D, Salomon M, D'Agostino RB, Belanger AJ, Kannel WB. Prognostic implications of baseline electrocardiographic features and their serial changes in subjects with left ventricular hypertrophy. Circulation. 1994;90: 1786-1793 (Pubitemid 24320926)
34. Okin PM, Devereux RB, Jern S, Kjeldsen SE, Julius S, Nieminen MS, et al. Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events. JAMA. 2004;292:2343-2349 (Pubitemid 39491918)
35. Wachtell K, Lehto M, Gerdts E, Olsen MH, Hornestam B, Dahlof B, et al. Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: The Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. J Am Coll Cardiol. 2005;45:712-719 (Pubitemid 40282586)
36. Wachtell K, Olsen MH, Dahlof B, Devereux RB, Kjeldsen SE, Nieminen MS, et al. Microalbuminuria in hypertensive patients with electrocardiographic left ventricular hypertrophy: The LIFE study. J Hypertens. 2002;20: 405-412 (Pubitemid 34913739)
37. Redon J, Cea-Calvo L, Lozano JV, Fernandez-Perez C, Navarro J, Bonet A, et al. Kidney function and cardiovascular disease in the hypertensive population: The ERIC-HTA study. J Hypertens. 2006;24:663-669
38. Johnson RJ, Kang DH, Feig D, Kivlighn S, Kanellis J, Watanabe S, et al. Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease? Hypertension. 2003;41:1183-1190 (Pubitemid 36706063)
39. Marrugat J, Solanas P, D'Agostino R, Sullivan L, Ordovas J, Cordon F, et al. Coronary risk estimation in Spain by using the Framingham scale. Rev Esp Cardiol. 2003;56:253-261 (Pubitemid 36527246)